Gelonghui, May 9 | Chengzhi Co., Ltd. (000990.SZ) said on the investor interactive platform that the synthetic biology business is one of the company's main businesses in the biomedical sector. Among them, production and sales of the company's D-ribose series products have grown rapidly in recent years. Currently, they dominate the global market and are widely used in medicine, nutrition and health care, food and beverage, clinical nutrition, etc. D-mannose developed by the company was mass-produced in 2023, and product sales have been growing steadily.
诚志股份(000990.SZ)：合成生物业务为公司生命医疗板块的主营业务之一
Chengzhi Co., Ltd. (000990.SZ): The synthetic biology business is one of the company's main businesses in the biomedical sector
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.